In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups ...

When the COVID-19 pandemic swept across the world in 2020, the mRNA vaccines came to the rescue of many people—but in the ...

“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...

For decades, the dream of fixing harmful mutations in mitochondrial DNA felt out of reach. Scientists have long known these ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Visitors to the Watson-Marlow Fluid Technology Solutions booth W15-2 at INTERPHEX Tokyo 2025 (July 9-11 at Tokyo Big Sight, Japan) can learn more about the new WMArchitect Interchangeable Parts ...

Monkeypox Vaccine and Treatment revenue is expected to grow at a CAGR of 10.20% from 2025 to 2032, reaching nearly USD 225.12 Mn by 2032.

Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments ...

Technology can be harnessed to design novel and enhanced molecules that address challenges in biotechnology or medicine.

“So, Donald Trump normally leans into stories in which there’s controversy,” Enten said. “This is a story he is trying to get ...

Australian scientists have successfully developed a research system that uses 'biological artificial intelligence' to design ...